NEW YORK (Reuters Health) - Vaccinating an entire population against anthrax before there is an immediate threat of a biological warfare attack is not cost-effective, results of statistical analysis suggest.
NEW YORK (Reuters Health) - Vaccinating an entire population against anthrax before there is an immediate threat of a biological warfare attack is not cost-effective, results of statistical analysis suggest.
